ERBB4 and neoplasm: Our findings suggest that miR-302b may be a novel CRI regulating miRNA that inhibits CRI critical pathway and downstream cytokines expression through targeting ERBB4, IRF2 and CXCR4, resulting in decrease of tumor growth.